Mood Dependent Effects of Ketamine on REM Eye Movements in Patients with Treatment Resistant Depression (TRD)

Hejazi, N., Yu, K., Park, L., Duncan, W., & Zarate, C. | Biological Psychiatry | 15 May 2017

Growing Evidence for Heterogeneous Synaptic Localization of 5-HT2A Receptors

Bécamel, C., Berthoux, C., Barre, A., & Marin, P. | ACS Chemical Neuroscience | 1 May 2017

Changes in Resting-State Global Brain Connectivity in LSD-Induced Altered States of Consciousness are Attributable to the 5-HT2A Receptor

Preller, K., Schleifer, C., Stämpfli, P., Krystal, J., Vollenweider, F., & Anticevic, A. | Biological Psychiatry | 29 April 2017

Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects

Mueller, F., Lenz, C., Dolder, P. C., Harder, S., Schmid, Y., Lang, U. E., ... & Borgwardt, S. | Translational Psychiatry | 4 April 2017

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Brown, R. T., Nicholas, C. R., Cozzi, N. V., Gassman, M. C., Cooper, K. M., Muller, D., ... & Hutson, P. R. | Clinical Pharmacokinetics | 28 March 2017

Psychedelics and the science of self-experience

Nour, M. M., & Carhart-Harris, R. L. | The British Journal of Psychiatry | 1 March 2017

Synthesis of New Harmine Isoxazoles and Evaluation of their Potential Anti-Alzheimer, Anti-inflammatory, and Anticancer Activities

Filali, I., Romdhane, A., Znati, M., B Jannet, H., & Bouajila, J. | Medicinal Chemistry | 1 March 2017

Indole Alkaloids from Plants as Potential Leads for Antidepressant Drugs: A Mini Review

Hamid, H. A., Ramli, A. N., & Yusoff, M. M. | Frontiers in Pharmacology | 28 February 2017

Effects of Hallucinogens on Neuronal Activity

Lladó-Pelfort, L., Celada, P., Riga, M. S., Troyano-Rodríguez, E., Santana, N., & Artigas, F. | Current Topics in Behavioural Neuroscience | 26 February 2017

22-azidosalvinorin A exhibits antidepressant-like effect in mice

Fajemiroye, J. O., Prabhakar, P. R., da Cunha, C. L., Costa, E. A., & Zjawiony, J. K. | European Journal of Pharmacology | 17 February 2017

Altered Insula Connectivity Under MDMA

Walpola, I. C., Nest, T., Roseman, L., Erritzoe, D., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. | Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology | 14 February 2017

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects

Dolder, P. C., Schmid, Y., Steuer, A. E., Kraemer, T., Rentsch, K. M., Hammann, F., & Liechti, M. E. | Clinical Pharmacokinetics | 14 February 2017

Short term changes in the proteome of human cerebral organoids induced by 5-methoxy-N,N-dimethyltryptamine

Dakic, V., Nascimento, J. M., Sartore, R. C., de Moraes Maciel, R., de Araujo, D. B., Ribeiro, S., ... & Rehen, S. K. | bioRxiv | 13 February 2017

Rapid antidepressant effect of ketamine correlates with astroglial plasticity in the hippocampus

Ardalan, M., Rafati, A. H., Nyengaard, J. R., & Wegener, G. | British Journal of Pharmacology | 8 February 2017

Sub-anesthetic doses of ketamine exert antidepressant-like effects and upregulate the expression of glutamate transporters in the hippocampus of rats

Zhu, X., Ye, G., Wang, Z., Luo, J., & Hao, X. | Neuroscience Letters | 3 February 2017

Effect of a Hallucinogenic Serotonin 5-HT2A Receptor Agonist on Visually-Guided, Hippocampal-Dependent Spatial Cognition in C57BL/6J Mice

Zhang, G., Cinalli, D., & Stackman, R. W. | Hippocampus | 1 February 2017

Prophylactic Ketamine Attenuates Learned Fear

McGowan, J. C., LaGamma, C. T., Lim, S. C., Tsitsiklis, M., Neria, Y., Brachman, R. A., & Denny, C. A. | Neuropsychopharmacology | 27 January 2017

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation

Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., ... & Vollenweider, F. X. | Current Biology | 26 January 2017

Crystal Structure of an LSD-Bound Human Serotonin Receptor

Wacker, D., Wang, S., McCorvy, J. D., Betz, R. M., Venkatakrishnan, A. J., Levit, A., ... & Shoichet, B. K. | Cell | 26 January 2017

The fibrinolytic system: A new target for treatment of depression with psychedelics

Idell, R. D., Florova, G., Komissarov, A. A., Shetty, S., Girard, R. B. S., & Idell, S. | Medical Hypotheses | 23 January 2017

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects

Vizeli, P., Schmid, Y., Prestin, K., zu Schwabedissen, H. E. M., & Liechti, M. E. | European Neuropsychopharmacology | 20 January 2017

Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens

Halberstadt, A. L. | Current Topics in Behavioral Neurosciences | 18 January 2017

Hyperthermia Severely Affects the Vascular Effects of MDMA and Metabolites in the Human Internal Mammary Artery In Vitro

Fonseca, D. A., Guerra, A. F., Carvalho, F., Fernandes, E., Ferreira, L. M., Branco, P. S., ... & Cotrim, M. D. | Cardiovascular Toxicology | 13 January 2017

Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?

Malcolm, B. J., & Lee, K. C. | Mental Health Clinician | 1 January 2017

Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects

Strajhar, P., Schmid, Y., Liakoni, E., Dolder, P. C., Rentsch, K. M., Kratschmar, D. V., ... & Liechti, M. E. | Journal of neuroendocrinology | 1 January 2017

Ketamine accelerates fear extinction via mTORC1 signaling

Girgenti, M. J., Ghosal, S., LoPresto, D., Taylor, J. R., & Duman, R. S. | Neurobiology of Disease | 30 December 2016

Harmine stimulates proliferation of human neural progenitors

Dakic, V., de Moraes Maciel, R., Drummond, H., Nascimento, J. M., Trindade, P., & Rehen, S. K. | PeerJ | 6 December 2016

Effects of the Natural β-Carboline Alkaloid Harmine, a Main Constituent of Ayahuasca, in Memory and in the Hippocampus: A Systematic Literature Review of Preclinical Studies

dos Santos, R. G., & Hallak, J. E. | Journal of psychoactive drugs | 5 December 2016

Discriminative Stimulus Properties of MDMA: The Role of Serotonin and Dopamine

Webster, J. | 1 December 2016

Effects of dextromethorphan on MDMA-induced serotonergic aberration in the brains of non-human primates using [123I]-ADAM/SPECT

Ma, K. H., Liu, T. T., Weng, S. J., Chen, C. F. F., Huang, Y. S., Chueh, S. H., ... & Huang, W. S. | Scientific Reports | 1 December 2016

Ecstasy research: will increasing observational data aid our understanding of MDMA?

Amoroso, T. | The Lancet Psychiatry | 1 December 2016

Ketamine for Treatment-Resistant Depression

Mathew, S. J., & Zarate Jr, C. A. | Springer International Publishing | 1 December 2016

Serotonergic Hallucinogen-Induced Visual Perceptual Alterations

Kometer, M., & Vollenweider, F. X. | Current Topics in Behavioral Neurosciences | 30 November 2016

Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies

Hermes, G., & Sanacora, G. | Ketamine for Treatment-Resistant Depression | 30 November 2016

Integrative analysis of sex differences in the rapid antidepressant effects of ketamine in preclinical models for individualized clinical outcomes

Saland, S. K., Duclot, F., & Kabbaj, M. | Current Opinion in Behavioral Sciences | 26 November 2016

d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology

De Gregorio, D., Comai, S., Posa, L., & Gobbi, G. | International Journal of Molecular Sciences | 23 November 2016

Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant

Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. | Neuroscience Bulletin | 22 November 2016

Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects

Lepow, L., Luckenbaugh, D. A., Park, L., Henter, I. D., & Zarate, C. A. | Journal of psychiatric research | 21 November 2016

Biosynthesis of the psychotropic plant diterpene salvinorin A: Discovery and characterization of the Salvia divinorum clerodienyl diphosphate synthase

Pelot, K. A., Mitchell, R., Kwon, M., Hagelthorn, D. M., Wardman, J. F., Chiang, A., ... & Zerbe, P. | The Plant Journal | 19 November 2016

The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens

Canal, C. E., & Murnane, K. S. | Journal of Psychopharmacology | 15 November 2016

Psychedelics as Medicines: An emerging new paradigm

Nichols, D. E., Johnson, M. W., & Nichols, C. D. | Clinical Pharmacology & Therapeutics | 4 November 2016

Rehabilitating LSD history in postwar America: Dilworth Wayne Woolley and the serotonin hypothesis of mental illness

Hewitt, K. | History of Science | 2 November 2016

MOLECULAR DOCKING STUDIES ON THE THERAPEUTIC TARGETS OF ALZHEIMER DISEASE (ACHE AND BCHE) USING NATURAL BIOACTIVE ALKALOIDS

Jyothi, P., & Yellamma, K. | International Journal of Pharmacy and Pharmaceutical Sciences | 1 November 2016

Classical hallucinogens and neuroimaging: A systematic review of human studies: Hallucinogens and neuroimaging

dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. | Neuroscience & Biobehavioral Reviews | 31 October 2016

A Case of 3,4-Dimethoxyamphetamine (3,4-DMA) and 3,4 Methylendioxymethamphetamine (MDMA) Toxicity with Possible Metabolic Interaction

Darracq, M. A., Thornton, S. L., Minns, A. B., & Gerona, R. R. | Journal of Psychoactive Drugs | 16 September 2016

The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells

Szabo, A., Kovacs, A., Riba, J., Djurovic, S., Rajnavolgyi, E., & Frecska, E. | Frontiers in Neuroscience | 14 September 2016

Ketamine Treatment and Global Brain Connectivity in Major Depression

Abdallah, C. G., Averill, L. A., Collins, K. A., Geha, P., Schwartz, J., Averill, C., ... & Iosifescu, D. V. | Neuropsychopharmacology | 8 September 2016

The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies

Vegting, Y., Reneman, L., & Booij, J. | Psychopharmacology | 28 August 2016

The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?

Bershad, A. K., Miller, M. A., Baggott, M. J., & de Wit, H. | Journal of Psychopharmacology | 25 August 2016

The antidepressant effect of ketamine: Mediated by AMPA receptors?

Inta, D., Sprengel, R., Borgwardt, S., Lang, U. E., & Gass, P. | European Neuropsychopharmacology | 20 August 2016

The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors

De Gregorio, D., Posa, L., Ochoa-Sanchez, R., McLaughlin, R., Maione, S., Comai, S., & Gobbi, G. | Pharmacological Research | 17 August 2016

Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study

Xu, X. | Doctoral dissertation, University of Pittsburgh | 8 August 2016

New use for an old drug: oral ketamine for treatment-resistant depression

Swiatek, K. M., Jordan, K., & Coffman, J. | BMJ Case Reports | 3 August 2016

Neurovascular Plasticity of the Hippocampus One Week after a Single Dose of Ketamine in Genetic Rat Model of Depression

Ardalan, M., Wegener, G., Polsinelli, B., Madsen, T. M., & Nyengaard, J. R. | Hippocampus | 21 July 2016

A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience

Gallimore, A. R. and Strassman, R. | Frontiers in Pharmacology | 30 June 2016

Ketamine abuse potential and use disorder

Liu, Y., Lin, D., Wu, B., & Zhou, W. | Brain research bulletin | 31 May 2016

Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors

Ponzoni, L., Daniela, B., & Sala, M. | Psychopharmacology | 16 June 2016

Letter to the Editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity

Hashimoto, K. | Psychological medicine | 10 June 2016

Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2’S,4’S)-lysergic acid 2,4-dimethylazetidide (LSZ)

Brandt, S. D., Kavanagh, P. V., Westphal, F., Elliott, S. P., Wallach, J., Colestock, T., ... & Halberstadt, A. L. | Drug testing and analysis | 6 June 2016

Serotonin antagonists fail to alter MDMA self-administration in rats

Schenk, S., Foote, J., Aronsen, D., Bukholt, N., Highgate, Q., Van de Wetering, R., & Webster, J. | Pharmacology Biochemistry and Behavior | 2 June 2016

Potential involvement of serotonergic signaling in ketamine’s antidepressant actions: A critical review

du Jardin, K. G., Müller, H. K., Elfving, B., Dale, E., Wegener, G., & Sanchez, C. | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2 June 2016

Ibogaine and addiction in the animal model, a systematic review and meta-analysis

Belgers, M., Leenaars, M., Homberg, J. R., Ritskes-Hoitinga, M., Schellekens, A. F. A., & Hooijmans, C. R. | Translational psychiatry | 31 May 2016

Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans

Nunes, A. A., dos Santos, R. G., Osório, F. L., Sanches, R. F., Crippa, J. A. S., & Hallak, J. E. | Journal of psychoactive drugs | 26 May 2016

Human Pharmacology of Mephedrone in Comparison to MDMA

Papaseit, E., Pérez-Mañá, C., Mateus, J. A., Pujadas, M., Fonseca, F., Torrens, M., ... & Farré, M. | Neuropsychopharmacology | 20 May 2016

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Rickly, A., Moning, O., Hoener, M., Liechti, M. | European Neuropsychopharmacology | 20 May 2016

Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report

Cloutier-Gill, L., Wood, E., Millar, T., Ferris, C., & Eugenia Socias, M. | Journal of Psychoactive Drugs | 18 May 2016

Psilocybin with psychological support for treatment-resistant depression

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., ... & Taylor, D. | The Lancet Psychiatry | 17 May 2016

Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., ... & Taylor, D. | The Lancet Psychiatry | 17 May 2016

Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression

Zhong, X., He, H., Zhang, C., Wang, Z., Jiang, M., Li, Q., ... & Huang, X. | Journal of Affective Disorders | 12 May 2016

Glutamate and GABA Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine

Lener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A., & Zarate, C. A. | Biological Psychiatry | 12 May 2016

Treatment of heroin dependence with ibogaine

Schellekens, A., Oosteren, T., Knuijver, T., & Belgers, M. | European Psychiatry | 12 May 2016

Depression: Ketamine steps out of the darkness

Malinow, R. | Nature | 4 May 2016

Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue—Behavioural, pharmacokinetic and metabolic studies in the Wistar rat

Horsley, R. R., Lhotkova, E., Hajkova, K., Jurasek, B., Kuchar, M., & Palenicek, T. | Brain Research Bulletin | 4 May 2016

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., ... & Dossou, K. S. | Nature | 4 May 2016

Neuropharmacology of N,N-Dimethyltryptamine

Carbonaro, T. M., & Gatch, M. B. | Brain Research Bulletin | 25 April 2016

Harmine stimulates neurogenesis of human neural cells in vitro

Dakic, V., de Moraes Maciel, R., Drummond, H., Nascimento, J. M., Trindade, P., & Rehen, S. K. | PeerJ Preprints | 14 April 2016

How psychoactive drugs shape human culture: a multi-disciplinary perspective

Wadley, G. | Brain Research Bulletin | 12 April 2016

Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution

Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., ... & Bullmore, E. | Current Biology | 11 April 2016

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Mithoefer, M. C., Grob, C. S., & Brewerton, T. D. | The Lancet Psychiatry | 5 April 2016

Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents

Mash, D. C., Ameer, B., Prou, D., Howes, J. F., & Maillet, E. L. | Journal of psychopharmacology (Oxford, England) | 4 April 2016

A systematic review of the effects of novel psychoactive substances ‘legal highs’ on people with severe mental illness

Gray, R., Bressington, D., Hughes, E., & Ivanecka, A. | Journal of Psychiatric and Mental Health Nursing | 1 April 2016

Depressant Effects of Salvia divinorum Involve Disruption of Physiological Sleep

González‐Trujano, M. E., Brindis, F., López‐Ruiz, E., Ramírez‐Salado, I., Martínez, A., & Pellicer, F. | Phytotherapy Research | 1 April 2016

Dimethyltryptamine (DMT): a biochemical Swiss Army knife in neuroinflammation and neuroprotection?

Szabo, A., & Frecska, E. | Neural Regeneration Research | 1 April 2016

Controversies of the effect of ketamine on cognition

Zhang, M. W., & Ho, R. | Frontiers in Psychiatry | 29 March 2016

Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans

Valle, M., Maqueda, A. E., Rabella, M., Rodríguez-Pujadas, A., Antonijoan, R. M., Romero, S., ... & Feilding, A. | European Neuropsychopharmacology | 25 March 2016

Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models

Kyzar, E. J., & Kalueff, A. V. | Zebrafish | 22 March 2016

Ayahuasca: pharmacology, neuroscience and therapeutic potential

Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., ... & Riba, J. | Brain Research Bulletin | 11 March 2016

Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.

Johnson, M. W., MacLean, K. A., Caspers, M. J., Prisinzano, T. E., & Griffiths, R. R. | Journal of psychopharmacology (Oxford, England) | 15 February 2016

Naltrexone but not ketanserin antagonizes the subjective, cardiovascular and neuroendocrine effects of salvinorin-A in humans

Maqueda, A. E., Valle, M., Addy, P. H., Antonijoan, R. M., Puntes, M., Coimbra, J., ... & Barker, S. | International Journal of Neuropsychopharmacology | 12 Februari 2016

Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients

Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Hung, N., ... & Howes, J. | Clinical Pharmacology in Drug Development | 10 February 2016

The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization

Frecska, E., Bokor, P., & Winkelman, M. | Frontiers in Pharmacology | 8 February 2016

Acute effects of LSD on circulating steroid levels in healthy subjects.

Strajhar, P., Schmid, Y., Liakoni, E., Dolder, P. C., Rentsch, K. M., Kratschmar, D. V., ... & Liechti, M. E. | Journal of Neuroendocrinology | 6 February 2016

Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms

Jiang, X. L., Shen, H. W., & Yu, A. M. | Pharmacological Reports | 5 Februari 2016

Psychedelics

Nichols, D. E. | Pharmacological reviews | 3 February 2016

The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study

Li, C. T., Chen, M. H., Lin, W. C., Hong, C. J., Yang, B. H., Liu, R. S., ... & Su, T. P. | Human Brain Mapping | 29 January 2016

How toxic is ibogaine?

Litjens, R. P., & Brunt, T. M. | Clinical Toxicology | 25 January 2016

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience

Pokorny, T., Preller, K. H., Kraehenmann, R., & Vollenweider, F. X. | European Neuropsychopharmacology | 22 January 2016

Oxytocin receptor gene variation predicts subjective responses to MDMA

Bershad, A. K., Weafer, J. J., Kirkpatrick, M. G., Wardle, M. C., Miller, M. A., & de Wit, H. | Social neuroscience | 20 January 2016

Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-NN-dimethyltryptamine

Halberstadt, A. L. | Pharmacology Biochemistry and Behavior | 15 January 2016

Genotoxic evaluations in Wistar rats of the hallucinogenic plant extract ayahuasca

Pic-Taylor, A., Junior, W. M., Souza-Filho, J., Grisolia, C. K., & Caldas, E. D. | International Journal of Phytomedicine | 1 January 2016

Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent

Frau, L., Costa, G., Porceddu, P. F., Khairnar, A., Castelli, M. P., Ennas, M. G., ... & Morelli, M. | Journal of neurochemistry | 1 January 2016

Effects of Long-Term Ayahuasca Administration on Memory and Anxiety in Rats

Favaro, V. M., Yonamine, M., Soares, J. C. K., & Oliveira, M. G. M. | PloS one | 30 December 2015

Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey

Schindler, E. A., Gottschalk, C. H., Weil, M. J., Shapiro, R. E., Wright, D. A., & Sewell, R. A. | Journal of psychoactive drugs | 23 November 2015

The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder

Amoroso, T. | Journal of Psychoactive Drugs | 18 November 2015

Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class

Dinger, J., Woods, C., Brandt, S. D., Meyer, M. R., & Maurer, H. H. | Toxicology Letters | 17 November 2015

Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression

Romeo, B., Choucha, W., Fossati, P., & Rotge, J. Y. | Psychiatry research | 29 October 2015

Binge Ethanol and MDMA Combination Exacerbates Toxic Cardiac Effects by Inducing Cellular Stress

Navarro-Zaragoza, J., Ros-Simó, C., Milanés, M. V., Valverde, O., & Laorden, M. L. | PloS one | 28 October 2015

The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT1A and 5-HT2A receptors.

Riga, M. S., Bortolozzi, A., Campa, L., Artigas, F., & Celada, P. | Neuropharmacology | 20 October 2015

The Ups and Downs of 3,4-Methylenedioxymethamphetamine: Linking Subjective Effects to Spontaneous Brain Function

de Wit, H., Gorka, S. M., & Phan, K. L. | Biological psychiatry | 15 October 2015

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity

Carhart-Harris, R. L., Murphy, K., Leech, R., Erritzoe, D., Wall, M. B., Ferguson, B., ... & Tanner, M. | Biological psychiatry. | 15 October 2015

Sex differences and serotonergic mechanisms in the behavioural effects of psilocin

Tylš, F., Páleníček, T., Kadeřábek, L., Lipski, M., Kubešová, A., & Horáček, J. | Behavioural pharmacology | 12 October 2015

Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)

Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Hoang, K., ... & Halberstadt, A. L. | Drug Testing and Analysis | 12 October 2015

Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson’s Disease?

Djamshidian, A., Bernschneider‐Reif, S., Poewe, W., & Lees, A. J. | Movement Disorders Clinical Practice | 6 October 2015

Kappa Opioids, Salvinorin A and Major Depressive Disorder

T Taylor and Francesca Manzella | Current Neuropharmacology | 1 October 2015

Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders

Costi, S., Van Dam, N. T., & Murrough, J. W. | Current Behavioral Neuroscience Reports | 01 October 2015

Acute Biphasic Effects of Ayahuasca

Schenberg E.E., Alexandre J.F.M., Filev R., Cravo A.M., Sato J.R., Muthukumaraswamy S.D., et al. | PLoS ONE | 30 September 2015

Ketamine for depression: evidence, challenges and promise

Zarate, C. A., & Niciu, M. J. | World Psychiatry | 25 September 2015

The Prosocial Effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled Studies in Humans and Laboratory Animals

Kamilar-Britt, P., & Bedi, G. | Neuroscience & Biobehavioral Reviews | 25 September 2015

[Psychedelics and quasi-psychedelics in the light of contemporary research: medical cannabis, MDMA, salvinorin A, ibogaine and ayahuasca]

Szabo, A., Kazai, A., Frecska, E., & Brys, Z. | official journal of the Hungarian Association of Psychopharmacology | 17 September 2015

3,4-Methylenedioxymethamphetamine facilitates fear extinction learning

Young, M. B., Andero, R., Ressler, K. J., & Howell, L. L. | Translational Psychiatry | 15 September 2015

Psychedelic medicine: a re-emerging therapeutic paradigm

Yensen, R., & Johnson, M. W. | Canadian Medical Association Journal | 08 Sep 2015

Psychedelic medicine: A re-emerging therapeutic paradigm

Tupper, K. W., Wood, E., Yensen, R., & Johnson, M. W. | CMAJ: Canadian Medical Association journal= journal de l'Association medicale canadienne | 08 September 2015

Salvinorin A, a kappa-opioid receptor (KOP-r) agonist hallucinogen: Pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders

Butelman, E., & Kreek, M. J. | Frontiers in Pharmacology | 08 Sep 2015

Harmine blocks herpes simplex virus infection through downregulating cellular NF-κB and MAPK pathways induced by oxidative stress

Chen, D., Su, A., Fu, Y., Wang, X., Lv, X., Xu, W., ... & Wu, Z. | Antiviral research | 5 September 2015

The paroxetine controversy: lessons for ketamine trials

Zhang, M. W., & Ho, R. C. | The lancet. Psychiatry | 1 September 2015

Psilocybin, psychological distress, and suicidality

Hendricks, P. S., Johnson, M. W., & Griffiths, R. R. | Journal of Psychopharmacology | 1 September 2015

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

Yang, C., Shirayama, Y., Zhang, J. C., Ren, Q., Yao, W., Ma, M., ... & Hashimoto, K. | Translational psychiatry | 1 September 2015

Effects of LSD on grooming behavior in serotonin transporter heterozygous (Sert+/−) mice

Kyzar, E. J., Stewart, A. M., & Kalueff, A. V. | Behavioural brain research | 1 Sep 2015

MDMA, cannabis, and cocaine produce acute dissociative symptoms

van Heugten-Van der Kloet, D., Giesbrecht, T., van Wel, J., Bosker, W. M., Kuypers, K. P., Theunissen, E. L., ... & Ramaekers, J. G. | Psychiatry research | 30 August 2015

The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity

Kraehenmann, R., Schmidt, A., Friston, K., Preller, K. H., Seifritz, E., & Vollenweider, F. X. | NeuroImage: Clinical | 22 Aug 2015

Noribogaine is a G-Protein Biased κ-Opioid Receptor Agonist

Maillet, E. L., Milon, N., Heghinian, M. D., Fishback, J., Schürer, S. C., Garamszegi, N., & Mash, D. C. | Neuropharmacology | 21 Aug 2015

LSD enhances the emotional response to music

Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., ... & Carhart-Harris, R. L. | Psychopharmacology | 11 August 2015

Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations

Kometer, M., Pokorny, T., Seifritz, E., & Vollenweider, F. X. | Psychopharmacology | 01 Aug 2015

Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches

Al Jurdi, R. K., Swann, A., & Mathew, S. J. | Current psychiatry reports | 1 August 2015

5-HTTLPR Genotype Moderates the Effects of Past Ecstasy Use on Verbal Memory Performance in Adolescent and Emerging Adults: A Pilot Study

Wright, N. E., Strong, J. A., Gilbart, E. R., Shollenbarger, S. G., & Lisdahl, K. M. | PloS one | 31 July 2015

The potential utility of some legal highs in CNS disorders

Davidson, C., & Schifano, F. | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 29 July 2015

Antidepressant mechanism of ketamine: perspective from preclinical studies

Scheuing, L., Chiu, C. T., Liao, H. M., & Chuang, D. M. | Frontiers in Neuroscience | 21 July 2015

Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats.

Grimm, O., Gass, N., Weber-Fahr, W., Sartorius, A., Schenker, E., Spedding, M., ... & Meyer-Lindenberg, A. | Psychopharmacology | 18 July 2015

Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain.

Spain, A., Howarth, C., Khrapitchev, A., Sharp, T., Sibson, N. R., & Martin, C. | Neuropharmacology | 17 July 2015

Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities

Szabo, A. | Frontiers in Immunology | 14 July 2015

Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder

Papakostas, G. I., & Ionescu, D. F. | Molecular psychiatry | 7 July 2015

Perceptual distortions and delusional thinking following ketamine administration are related to increased pharmacological MRI signal changes in the parietal lobe

Stone, J., Kotoula, V., Dietrich, C., De Simoni, S., Krystal, J. H., & Mehta, M. A. | Journal of Psychopharmacology | 6 July 2015

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression

Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., & Nemeroff, C. B. | American Journal of Psychiatry | 29 June 2015

Pharmacokinetics and concentration-effect relationship of oral LSD in humans

Dolder, P. C., Schmid, Y., Haschke, M., Rentsch, K. M., & Liechti, M. E. | International Journal of Neuropsychopharmacology | 24 June 2015

Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant

Ballard, E. D., Luckenbaugh, D. A., Richards, E. M., Walls, T. L., Brutsché, N. E., Ameli, R., ... & Zarate, C. A. | Journal of psychiatric research | 16 June 2015

Ketamine and Phencyclidine: the good, the bad and the unexpected

Lodge, D., & Mercier, M. S. | British journal of pharmacology | 15 June 2015

Chronic MDMA induces neurochemical changes in the hippocampus of adolescent and young adult rats: Down-regulation of apoptotic markers

García-Cabrerizo, R., & García-Fuster, M. J. | Neurotoxicology | 9 June 2015

Antidepressant drug action – From rapid changes on network function to network rewiring

Rantamäki, T., & Yalcin, I. | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 9 June 2015

In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept

Rodriguez, C. I., Kegeles, L. S., Levinson, A., Ogden, R. T., Mao, X., Milak, M. S., ... & Simpson, H. B. | Psychiatry Research: Neuroimaging | 6 June 2015

Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans

Maqueda, A. E., Valle, M., Addy, P. H., Antonijoan, R. M., Puntes, M., Coimbra, J., ... & Riba, J. | International Journal of Neuropsychopharmacology | 5 June 2015

The use of ketamine for the treatment of depression in the context of psychotic symptoms

da Frota Ribeiro, C. M., Sanacora, G., Hoffman, R., & Ostroff, R. | Biological Psychiatry | 4 June 2015

Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat.

Pic-Taylor, A., da Motta, L. G., de Morais, J. A., Junior, W. M., Santos, A. D. F. A., Campos, L. A., ... & Caldas, E. D. | Behavioural processes | 3 June 2015

MDMA for the treatment of mood disorder: all talk no substance?

Patel, R., & Titheradge, D. | Therapeutic Advances in Psychopharmacology | 1 June 2015

Single-Dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression

Kantrowitz, J. T., Halberstam, B., & Gangwisch, J. | The Journal of clinical psychiatry | 1 June 2015

The positive effect on ketamine as a priming adjuvant in antidepressant treatment.

Melo, A., Kokras, N., Dalla, C., Ferreira, C., Ventura-Silva, A. P., Sousa, N., & Pêgo, J. M. | Translational Psychiatry | 26 May 2015

Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential

Rucker, J. J. | BMJ | 26 May 2015

Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin

Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. | Human brain mapping | 22 May 2015

Noribogaine reduces nicotine self-administration in rats

Chang, Q., Hanania, T., Mash, D. C., & Maillet, E. L. | Journal of Psychopharmacology | 20 May 2015

Ketamine induces a robust whole-brain connectivity pattern that can be differentially modulated by drugs of different mechanism and clinical profile

Joules, R., Doyle, O. M., Schwarz, A. J., O’Daly, O. G., Brammer, M., Williams, S. C., & Mehta, M. A. | Psychopharmacology | 19 May 2015

Immunomodulatory activity of ketamine in human astroglial A172 cells: Possible relevance to its rapid antidepressant activity.

Yuhas, Y., Ashkenazi, S., Berent, E., & Weizman, A. | Journal of neuroimmunology | 15 May 2015

Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression.

Andrade, C. | The Journal of clinical psychiatry | May 2015

Therapeutic potential of psychedelic agents

Nour, M. M., & Krzanowski, J. | The British Journal of Psychiatry | 1 May 2015

MDMA for the treatment of mood disorder: all talk no substance?

Patel, R., & Titheradge, D. | Therapeutic Advances in Psychopharmacology | 1 May 2015

Ibogan, Tacaman, and Cytotoxic Bisindole Alkaloids from Tabernaemontana. Cononusine, an Iboga Alkaloid with Unusual Incorporation of a Pyrrolidone Moiety

Lim, K. H., Raja, V. J., Bradshaw, T. D., Lim, S. H., Low, Y. Y., & Kam, T. S. | Journal of natural products | 28 April 2015

Ketamine-A Narrative Review of Its Uses in Medicine

Radvansky, B. M., Puri, S., Sifonios, A. N., Eloy, J. D., & Le, V. | American Journal of Therapeutics | Apr 24 2015

Ketamine-induced modulation of the thalamo-cortical network in healthy volunteers as a model for schizophrenia

Höflich, A., Hahn, A., Küblböck, M., Kranz, G. S., Vanicek, T., Windischberger, C., ... & Guertel, W. | The international journal of neuropsychopharmacology | 20 April 2015

A Note on the Docking of some Hallucinogens to the 5-HT2A Receptor

Gómez-Jeria, J. S., & Robles-Navarro, A. | Journal of Computational Methods in Molecular Design | April 2015

Mania following use of ibogaine: A case series

Marta, C. J., Ryan, W. C., Kopelowicz, A., & Koek, R. J. | The American Journal on Addictions | 14 April 2015

Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review

Iadarola, N. D., Niciu, M. J., Richards, E. M., Voort, J. L. V., Ballard, E. D., Lundin, N. B., ... & Zarate, C. A. | Therapeutic Advances in Chronic Disease | 13 April 2015

The use of ketamine as an antidepressant: a systematic review and meta-analysis

Coyle, C. M., & Laws, K. R. | Human Psychopharmacology: Clinical and Experimental | 7 April 2015

Protecting the human rights of people who use psychedelics

Krebs, T. S. | The Lancet | 1 April 2015

Serotonergic psychedelics temporarily modify information transfer in humans

Alonso, J. F., Romero, S., Mañanas, M. À., & Riba, J. | International Journal of Neuropsychopharmacology | 28 March 2015

Current knowledge on the neurobiology of classical hallucinogens and their relevance for the treatment of mood and anxiety disorders

Kraehenmann, R. | European Psychiatry | 28 Mar 2015

5HT2a Receptors – a New Target for Depression?

Nutt, D. | European Psychiatry | 28 March 2015

The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-making

Preller, K. H., Pokorny, T., Krähenmann, R., Dziobek, I., Stämpfli, P., & Vollenweider, F. X. | European Psychiatry | 28 March 2015

MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults

Danforth, A. L., Struble, C. M., Yazar-Klosinski, B., & Grob, C. S. | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 25 March 2015

Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary

Sessa, B., & Fischer, F. M. | Underground MDMA-, LSD-and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary | 24 March 2015

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report

Osório, F. D. L., Sanches, R. F., Macedo, L. R., Dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., ... & Hallak, J. E. | Revista Brasileira de Psiquiatria | 20 March 2015

Classic hallucinogens in the treatment of addictions

Bogenschutz, M. P., & Johnson, M. W. | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 14 March 2015

Prosocial effects of MDMA: A measure of generosity

Kirkpatrick, M., Delton, A. W., de Wit, H., & Robertson, T. E. | Journal of Psychopharmacology | 3 March 2015

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants

Abdallah, C. G., Averill, L. A. and Krystal, J. H. | Annals of the New York Academy of Sciences | 27 Feb 2015

Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction

Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. | Current Drug Abuse Reviews | 23 February 2015

A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects

Liester, M. B. | Current Drug Abuse Reviews | 23 February 2015

What Can Neuroscience Tell Us About the Potential of Psychedelics in Healthcare?

Mackenzie, R. | Current Drug Abuse Reviews | 23 February 2015

Editorial (Thematic Issue: Introduction to ‘Beneficial Effects of Psychedelics with a Special Focus on Addictions’)

Breeksema, J. J., & Kortekaas, R. | Current Drug Abuse Reviews | 23 February 2015

The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network

Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J., Hallak, J. A., ... Araujo, D. B. | PLoS One | 18 February 2015

The subjective experience of acute, experimentally-induced Salvia divinorum inebriation

Addy, P. H., Garcia-Romeu, A., Metzger, M., & Wade, J. | Journal of Psychopharmacology | 17 February 2015

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder

Murrough, J. W., Collins, K. A., Fields, J., DeWilde, K. E., Phillips, M. L., Mathew, S. J., ... & Iosifescu, D. V. | Translational psychiatry | 17 February 2015

Neural correlates of change in major depressive disorder anhedonia following open-label ketamine

Lally, N., Nugent, A. C., Luckenbaugh, D. A., Niciu, M. J., Roiser, J. P., & Zarate, C. A. | Journal of Psychopharmacology | 17 February 2015

Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?

Majić, T., Schmidt, T. T., & Gallinat, J. | Journal of Psychopharmacology | 9 February 2015

Ex vivo effects of ibogaine on the activity of antioxidative enzymes in human erythrocytes

Nikolić-Kokić, A., Oreščanin-Dušić, Z., Spasojević, I., Slavić, M., Mijušković, A., Paškulin, R., ... & Blagojević, D. P. | Journal of ethnopharmacology | 7 Februari 2015

Ex vivo effects of ibogaine on the activity of antioxidative enzymes in human erythrocytes

Nikolić-Kokić, A., Oreščanin-Dušić, Z., Spasojević, I., Slavić, M., Mijušković, A., Paškulin, R., ... & Blagojević, D. P. | Journal of ethnopharmacology | 7 February 2015

The Effect of Repeated Ketamine Infusion Over Facial Emotion Recognition in Treatment-Resistant Depression: A Preliminary Report

Shiroma, P. R., Albott, C. S., Johns, B., Thuras, P., Wels, J., & Lim, K. O. | The Journal of Neuropsychiatry and Clinical Neurosciences | 6 February 2015

New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

McKenna, D., & Riba, J. | Current Topics in Behavioral Neuroscience | 6 February 2015

Drug models of schizophrenia

Steeds, H., Carhart-Harris, R. L., & Stone, J. M. | Therapeutic Advances in Psychopharmacology | 5 February 2015

Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers

Glue, P., Winter, H., Garbe, K., Jakobi, H., Lyudin, A., Lenagh‐Glue, Z., & Hung, C. T. | The Journal of Clinical Pharmacology | 4 February 2015

Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia

Xu, K., Krystal, J. H., Ning, Y., He, H., Wang, D., Ke, X., ... & Fan, N. | Journal of psychiatric research | February 2015

Antidepressant actions of ketamine: from molecular mechanisms to clinical practice

Monteggia, L. M., & Zarate, C. | Current opinion in neurobiology | 1 February 2015

The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation

Koenig, X., & Hilber, K. | Molecules | 29 January 2015

Editorial (Thematic Issue: Introduction to ‘Beneficial Effects of Psychedelics with a Special Focus on Addictions’)

Kortekaas, R., & Breeksema, J. J. | Current Drug Abuse Reviews | 28 January 2015

Ayahuasca, Psychedelic Studies and Health Sciences: The Politics of Knowledge and Inquiry into an Amazonian Plant Brew

Tupper, K. W., & Labate, B. C. | Current Drug Abuse Reviews | 28 January 2015

Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca

Winkelman, M. | Current Drug Abuse Reviews | 28 January 2015

A Qualitative Report on the Subjective Experience of Intravenous Psilocybin Administered in an fMRI Environment

Turton, S., Nutt, D. J., & Carhart-Harris, R. L. | Current Drug Abuse Reviews | 28 January 2015

Salvinorin A and Related Compounds as Therapeutic Drugs for Psychostimulant-Related Disorders

dos Santos, R. G., Crippa, J. A., Machado-de-Sousa, J. P., & Hallak, J. E. | Current Drug Abuse Reviews | 28 January 2015

Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans

Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., ... & Riba, J. | European Neuropsychopharmacology | 16 January 2015

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. | Journal of Psychopharmacology | 13 January 2015

Recreational Use, Analysis and Toxicity of Tryptamines.

Tittarelli, R., Mannocchi, G., Pantano, F., & Saverio Romolo, F. | Current Neuropharmacology | 13 January 2015

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A, Pommy, J. A., Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J. | Journal of Psychopharmacology | 13 January 2015

Making a medicine out of MDMA

Sessa, B., & Nutt, D. | The British Journal of Psychiatry | 5 January 2015

Serotonin 5-HT₂ receptor activation prevents allergic asthma in a mouse model.

Nau, F., Miller, J., Saravia, J., Ahlert, T., Yu, B., Happel, K. I., ... & Nichols, C. D. | American Journal of Physiology-Lung Cellular and Molecular Physiology | 1 January 2015

Ketamine interactions with biomarkers of stress: A randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men

Mahani, N. K., Niesters, M., van Osch, M. J., Oitzl, M., Veer, I., de Rooij, M., ... & Dahan, A. | NeuroImage | 29 December 2014

Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression

Drewniany, E., Han, J., Hancock, C., Jones, R. L., Lim, J., Nemat Gorgani, N., ... & Raffa, R. B. | Journal of Clinical Pharmacy and Therapeutics | 26 December 2014

Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues

Riley, A. P., Groer, C. E., Young, D., Ewald, A. W., Kivell, B. M., & Prisinzano, T. E. | Journal of medicinal chemistry | 26 December 2014

Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability

Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C. T., & Friedhoff, L. | The Journal of Clinical Pharmacology | 22 December 2014

Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial

Murrough, J. W., Burdick, K. E., Levitch, C. F., Perez, A. M., Brallier, J. W., Chang, L. C., ... & Iosifescu, D. V. | Neuropsychopharmacology | 17 December 2014

Nitrous Oxide for Treatment-Resistant Major Depression: a Proof-of-Concept Trial

Nagele, P., Duma, A., Kopec, M., Gebara, M. A., Parsoei, A., Walker, M., ... & Conway, C. | Biological Psychiatry | 9 December 2014

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects

Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., ... & Liechti, M. E. | Biological psychiatry | 29 November 2014

A single infusion of ketamine improves depression scores in patients with anxious bipolar depression

Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., & Zarate, C. A. | Bipolar disorders | 14 November 2014

Ketamine and other potential glutamate antidepressants

Dutta, A., McKie, S., & Deakin, J. W. | Psychiatry research | 12 November 2014

Psilocybin and Obsessive Compulsive Disorder

Wilcox, J. A. | Journal of psychoactive drugs | 11 November 2014

LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects

Gasser, P., Kirchner, K., & Passie, T. | Journal of Psychopharmacology | 11 November 2014

Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety

Ballard, E. D., Ionescu, D. F., Voort, J. L. V., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., ... & Zarate, C. A. | Journal of psychiatric research | November 2014

Effects of ecstasy on cooperative behaviour and perception of trustworthiness: A naturalistic study

Stewart, L. H., Ferguson, B., Morgan, C. J. A., Swaboda, N., Jones, L., Fenton, R., ... & Curran, H. V. | Psychopharmacology | November 2014

M1 and M2 Muscarinic Receptor Subtypes Regulate Antidepressant-Like Effects of the Rapidly Acting Antidepressant Scopolamine

Witkin, J. M., Overshiner, C., Li, X., Catlow, J. T., Wishart, G. N., Schober, D. A., ... & Felder, C. C. | Journal of Pharmacology and Experimental Therapeutics | November 2014

Harmine mediated neuroprotection via evaluation of glutamate transporter 1 in a rat model of global cerebral ischemia.

Sun, P., Zhang, S., Li, Y., & Wang, L. | Neuroscience letters | 7 November 2014

On the transmethylation hypothesis: stress, N,N-dimethyltryptamine, and positive symptoms of psychosis

Grammenos, D., & Barker, S. A. | Journal of Neural Transmission | 2 November 2014

Single Ketamine Infusion and Neurocognitive Performance in Bipolar Depression

Permoda-Osip, A., Kisielewski, J., Bartkowska-Sniatkowska, A., & Rybakowski, J. K. | Pharmacopsychiatry | 27 October 2014

Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats

Sakashita, Y., Abe, K., Katagiri, N., Kambe, T., Saitoh, T., Utsunomiya, I., ... & Taguchi, K. | Biological and Pharmaceutical Bulletin | 24 October 2014

Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

Sanacora, G., & Schatzberg, A. F. | Neuropsychopharmacology | 22 October 2014

Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics

Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. | Medicine | 17 October 2014

Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression

Lally, N., Nugent, A. C., Luckenbaugh, D. A., Ameli, R., Roiser, J. P., & Zarate, C. A. | Translational psychiatry | 14 October 2014

A functional selectivity mechanism at the serotonin-2A GPCR involves ligand-dependent conformations of intracellular loop 2

Perez-Aguilar, J. M., Shan, J., LeVine, M. V., Khelashvili, G., & Weinstein, H. | Journal of the American Chemical Society | October 2014

Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor

Polepally, P. R., Setola, V., Vardy, E., Roth, B. L., Mosier, P. D., & Zjawiony, J. | Planta Medica | 6 October 2014

Treating drug dependence with the aid of ibogaine: A retrospective study

Schenberg, E.E., de Castro Comis, M.A., Rasmussen Chaves, B. & da Silveira, D. X. | Journal of Psychopharmacology | 29 September 2014

Back to the future: A return to psychedelic treatment models for addiction

Hendricks, P. S. | Journal of Psychopharmacology | 24 September 2014

LSD enhances suggestibility in healthy volunteers

Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A. & Nutt, D. J. | Psychopharmacology | 23 September 2014

The role of ketamine in treatment-resistant depression: a systematic review

Serafini, G., H Howland, R., Rovedi, F., Girardi, P., & Amore, M. | Current neuropharmacology | 12 September 2014

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. | Journal of Psychopharmacology | 11 September 2014

Acute effects of MDMA on autonomic cardiac activity and their relation to subjective prosocial and stimulant effects

Clark, C. M., Frye, C. G., Wardle, M. C., Norman, G. J., & Wit, H. | Psychophysiology | 10 September 2014

Blood d-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine

Hashimoto, K. | Psychopharmacology | 5 September 2014

Ketamine safety and tolerability in clinical trials for treatment-resistant depression

Wan, L. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Iosifescu, D. V., Chang, L. C., ... & Murrough, J. W. | The Journal of clinical psychiatry | 2 September 2014

Ketamine administration in depressive disorders: a systematic review and meta-analysis

Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M. ... Boyer, L. | Psychopharmacology | 20 July 2014

The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice

Carbonaro, T. M., Eshleman, A. J., Forster, M. J., Cheng, K., Rice, K. C., & Gatch, M. B. | Psychopharmacology | 3 July 2014

Enhanced repertoire of brain dynamical states during the psychedelic experience

Tagliazucchi, E., Carhart-Harris, R. L., Leech, R., Nutt, D., & Chialvo, D. R. | Human Brain Mapping | 2 July 2014

(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function

Paul, R. K., Singh, N. S., Khadeer, M., Moaddel, R., Sanghvi, M., Green, C. E., ... & Wainer, I. W. | The Journal of the American Society of Anesthesiologists | 1 July 2014

Harmine for catatonic schizophrenia. A forgotten experiment

Hostiuc, S., Buda, O., & Ion, D. A. | Schizophrenia research | 30 June 2014

Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder

Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., ... & Charney, D. S. | JAMA psychiatry | June 2014

Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases

Litjens, R. P., Brunt, T. M., Alderliefste, G. J., & Westerink, R. H. | European Neuropsychopharmacology | June 2014

Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?

Rolland, B., Jardri, R., Amad, A., Thomas, P., Cottencin, O., & Bordet, R. | Biomed Research International | 4 June 2014

The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers

Roseman, L., Leech, R., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. | Frontiers in Human Neuroscience | 27 May 2014

The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat

Rambousek, L., Palenicek, T., Vales, K., & Stuchlik, A. | Frontiers in Behavioral Neuroscience | 16 May 2014

Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes

Blough, B. E., Landavazo, A., Decker, A. M., Partilla, J. S., Baumann, M. H,. & Rothman, R. B. | Psychopharmacology | 7 May 2014

Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling

Buchborn, T., Schröder, H., Höllt, V., & Grecksch, G. | Journal of Psychopharmacology | 30 April 2014

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers

Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenwieder, F. X. | Biological Psychiatry | 26 April 2014

Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles

Baumeister, D., Barnes, G., Giaroli, G., & Tracy, D. | Therapeutic Advances in Psychopharmacology | 17 March 2014

MDMA and the “Ecstasy Paradigm”

Cole, J. C. | Journal of Psychoactive Drugs | 11 March 2014

The Potential Dangers of Using MDMA for Psychotherapy

Parrott, A. C. | Journal of Psychoactive Drugs | 11 March 2014

Therapeutic infusions of ketamine: Do the psychoactive effects matter?

Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. | Drug and alcohol dependence | 18 Feb 2014

Do the dissociative side effects of ketamine mediate its antidepressant effects?

Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., ... & Zarate, C. A. | Journal of affective disorders | 18 Feb 2014

MDMA decreases the effects of simulated social rejection

Frye, C. G., Wardle, M. C., Norman, G. J., & de Wit, H. | Pharmacology Biochemistry and Behavior | February 2014

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. | Frontiers in Human Neuroscience | 3 February 2014

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labelling and Blood Oxygen Level-Dependent Resting-State Functional Connectivity

Carhart-Harris, R. L., Murphy, K., Leech, R., Erritzoe, D., Wall, M. B., Ferguson, B., ... Nutt, D. J. | Biological Psychiatry | 10 January 2014

IJTS Special Topic Section: Ketamine ● Ketamine (IM) Assisted Psychotherapy (KAP): A Model for Informed Consent

Wolfson, P. E. | International Journal of Transpersonal Studies | 2014

IJTS Special Topic Section: Ketamine ● Psychedelic Experiential Pharmacology: Pioneering Clinical Explorations with Salvador Roquet

Wolfson, P. E. | International Journal of Transpersonal Studies | 2014

IJTS Special Topic Section: Ketamine ● Regarding the Transpersonal Nature of Ketamine Therapy: An Approach to the Work

Becker, J. | International Journal of Transpersonal Studies | 2014

IJTS Special Topic Section: Ketamine ● Making Ketamine Work in the Long Run

Early, T. S. | International Journal of Transpersonal Studies | 2014

IJTS Special Topic Section: Ketamine ● Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications

Kolp, E., Krupitsky, E., Sylvester, M., Kolp, A., Friedman, H. L., Jansen, K., & Young, M. S. | International Journal of Transpersonal Studies | 2014

IJTS Special Topic Section: Ketamine ● Ketamine for Depression: A Mixed-Methods Study

Wolfson, P. E. | International Journal of Transpersonal Studies | 2014

IJTS Special Topic Section: Ketamine ● Ketamine and Depression: A Review

Ryan, W. C., Marta, C. J., & Koek, R. J. | International Journal of Transpersonal Studies | 2014

IJTS Special Topic Section: Ketamine ● Ketamine—Its History, Uses, Pharmacology, Therapeutic Practice, and an Exploration of its Potential as a Novel Treatment for Depression

Wolfson, P.E. | The International Journal of Transpersonal Studies | 2014

Psilocybin – Summary of knowledge and new perspectives

Tylš, F., Páleníček, T., & Horáček, J. | European Neuropsychopharmacology | 17 December 2013

Ibogaine: a review

Alper, K. R. | The alkaloids: Chemistry and Biology | 4 December 2013

Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample

Winstock, A. R., Kaar, S., & Borschmann, R. | Journal of Psychopharmacology | 27 November 2013

Reviewing the ketamine model for schizophrenia

Frohlich, J., & van Horn, J. D. | Journal of Psychopharmacology | 20 November 2013

Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy

Caddy, C., Giaroli, G., White, T. P., Sukhwinder, S. S. & Tracy, D. K. | Therapeutic Advances in Psychopharmacology | 22 October 2013

Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia

Brogaard, B. | Frontiers in Human Neuroscience | 21 October 2013

Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review

de Kleine, R. A., Rothbaum, B. O., & van Minnen, A. | European Journal of Psychotraumatoly | 17 October 2013

Effect of Iboga Alkaloids on µ-Opioid Receptor-Coupled G Protein Activation

Antonio, T., Childers, S. R., Rothman, R. B., Dersch, C. M., King, C., Kuehne, M., ... & Alper, K. | PloS ONE | 16 October 2013

Effective interventions in the problematic use of alcohol and other drugs

Lefio L. Á., Villarroel S.R., Rebolledo C., Zamorano P., & Rivas K. | Revista Panamericana de Salud Pública | 1 October 2013

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial

Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., ... Mathew, S. J. | American Journal of Psychiatry | October 2013

Ketamine for Treatment-Resistant Depression: Ready or Not for Clinical Use?

Rush, A. J. | American Journal of Psychiatry | 1 October 2013

Broadband cortical desynchronization underlies the human psychedelic state

Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J., Brookes, M. J., Williams, T. M., Errtizoe, D., ... & Feilding, A. | The Journal of Neuroscience | 18 September 2013

A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment

Burdick, B. V., & Adinoff, B. | The American Journal of Drug and Alcohol Abuse | September 2013

Spatiotemporal Brain Dynamics of Emotional Face Processing Modulations Induced by the Serotonin 1A/2A Receptor Agonist Psilocybin

Bernasconi, F., Schmidt, A., Pokorny, T., Kometer, M., Seifritz, E., & Vollenweider, F. X. | Cerebral Cortex | 16 July 2013

Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users.

Bouso, J. C., Fábregas, J. M., Antonijoan, R. M., Rodríguez-Fornells, A., & Riba, J. | Psychopharmacology | 21 June 2013

2C or not 2C: phenethylamine designer drug review

Dean, B. V., Stellpflug, S. J., Burnett, A. M., & Engebretsen, K. M. | Journal of Medical Toxicology | 9 June 2013

NMDA Receptor Antagonists for Treatment of Depression

Ates-Alagoz, Z., & Adejare, A. | Pharmaceuticals | 3 April 2013

The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor

Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X. P., Setola, V., Treble, R., & Iversen, L. | PLoS One | 19 March 2013

Hallucinogen persisting perception disorder: what do we know after 50 years?

Halpern, J. H., & Harrison, G. P. Jr. | Drug and Alcohol Dependence | 1 March 2013

Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin

Bogenschutz, M. P. | Current Drug Abuse Reviews | 1 March 2013

Ibogaine in the Treatment of Substance Dependence

Brown, T. K. | Current Drug Abuse Reviews | 1 March 2013

Salvia divinorum: A Psychopharmacological Riddle and a Mind-Body Prospect

Diaz, J-L. | Current Drug Abuse Reviews | 1 March 2013

Can MDMA Play a Role in the Treatment of Substance Abuse?

Jerome, L, Schuster, S., & Yazar-Klosinski, B. B. | Current Drug Abuse Reviews | 1 March 2013

Role of the 5-HT2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice

Halberstadt, A. L., Powell, S. B., & Geyer, M. A. | Neuropharmacology | 29 January 2013

Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors

Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. | Biological Psychiatry | 19 December 2012

Durability of improvement in posttraumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study

Mithoefer, M.C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., ... Doblin, R. | Journal of Psychopharmacology | 20 November 2012

A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)

Oehen, P., Traber, R., Widmer, V., & Schnyder, U. | Journal of Psychopharmacology | 31 October 2012

Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions

Liester, M. B., & Prickett, J. I. | Journal of psychoactive drugs | 2 August 2012

Research on psychedelic substances

Brandt, S. D., & Passie, T. | Drug testing and analysis | 06 Jul 2012

Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies

Ross, S. | Psychiatric Clinics of North America | 1 June 2012

Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca

Riba, J., McIlhenny, E. H., Valle, M., Bouso, J. C., & Barker, S. A. | Drug testing and analysis | 19 April 2012

Replication of Ketamine’s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

Zarate Jr., A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., ... Luckenbaugh, D. A. | Biological Psychiatry | 31 January 2012

Could MDMA be useful in the treatment of post-traumatic stress disorder?

Sessa, B. | Progress in Neurology and Psychiatry | 15 December 2011

Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.

Shen, H. W. , Jiang, X. L., Winter, J. C., Yu, A. M.| Current Drug Metabolism | 1 October 2011

Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers

Quednow, B. B., Kometer, M., Geyerand, M. A., & Vollenweider, F. X. | Neuropsychopharmacology | 28 September 2011

Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence

Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V., Romanova, T. N., Slavina, T. Y., & Grinenko, A. Y. | Journal of psychoactive drugs | 08 Sep 2011

Reassessing the cultural and psychopharmacological significance of Banisteriopsis caapi: preparation, classification and use among the Piaroa of Southern Venezuela

Rodd, R. | Journal of psychoactive drugs | 8 September 2011

Bringing Ayahuasca to the Clinical Research Laboratory

Riba, J., & Barbanoj, M. J. | Journal of Psychoactive Drugs | 7 September 2011

A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department

Larkin, G. L., & Beautrais, A. L. | International Journal of Neuropsychopharmacology | 1 September 2011

Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain

Réus, G. Z., Stringari, R. B., Ribeiro, K. F., Ferraro, A. K., Vitto, M. F., Cesconetto, P., ... Quevedo, J. | Behavioural Brain Research, 221 | 1 August 2011

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. | Psychopharmacology | 15 June 2011

In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin 2A Receptor Binding in MDMA and Hallucinogen Users

Erritzoe, D., Frokjaer, V. G., Holst, K. K., Christoffersen, M., Johansen, S. S., Svarer, C., ... Knudsen, G. M. | Archives of General Psychiatry | 6 June 2011

The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations

Kometer, M., Cahn, B. R., Andel, D., Carter, O. L., & Vollenweider, F. X. | Biological Psychiatry | 1 March 2011

Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs

Halpern, J. H., Sherwood, A. R., Hudson, J. I., Gruber, S. Kozin, D., & Pope Jr., H. G. | Addiction | 15 February 2011

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. | Archives of General Psychiatry | 3 January 2011

Characterization of behavioral and endocrine effects of LSD on zebrafish

Grossman, L., Utterback, E., Stewarta, A., Gaikwada, S., Chunga, K. M., Suciua, C., ... Kalueff, A. V. | Behavioural Brain Research, 214 | 25 December 2010

Is Ecstasy an “Empathogen”? Effects of ±3,4-Methylenedioxymethamphetamine on Prosocial Feelings and Identification of Emotional States in Others

Bedia, G., Hymana, D., & de Wit, H. | Biological Psychiatry | 15 December 2010

Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial

Mendelson, J. E., Coyle, J. R., Lopez, J.C., Baggott, M. J., Flower, K., Everhart, E. T., ... Cohen, B. M. | Psychopharmacology | 8 December 2010

Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum

Johnson, M. W., Maclean, K.A., Reissig, C. R., Prisinzano, T. E., & Griffiths, R. R. | Drug and Alcohol Dependence | 3 December 2010

Serotonin, But Not N-Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling Complex In Vivo

Schmid, C. L., & Bohn, L. M. | The Journal of Neuroscience | 6 October 2010

Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague–Dawley rats

Killingera, B. A., Peeta, M. M., & Baker, L. E. | Pharmacology Biochemistry and Behavior | September 2010

Glutamatergic Model Psychoses: Prediction Error, Learning, and Inference

Corlett, P. R., Honey, G. D., Krystal, J. H., & Fletcher, P. C. | Neuropsychopharmacology Reviews | 22 September 2010

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. | Journal of Psychopharmacology | 20 September 2010

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Vollenweider, F. X., & Kometer, M. | Nature Reviews Neuroscience | September 2010

Intrahippocampal LSD accelerates learning and desensitizes the 5-HT2A receptor in the rabbit

Romano, A. G., Quinn, J. L., Li, L., Dave, K. D., Schindler, E. A., Aloyo, V. J., & Harvey, J. A. | Psychopharmacology | 9 September 2010

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

Diazgranados, N., Ibrahim, L. Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., ... Zarate Jr., Z. A. | Archives of General Psychiatry | August 2010

The safety and efficacy of ±3,4-methylenedioxymethamphetamineassisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder

Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. | Journal of Psychopharmacology | 19 July 2010

Composition, Standardization and Chemical Profiling of Banisteriopsis caapi, a Plant for the Treatment of Neurodegenerative Disorders Relevant to Parkinson’s Disease

Wang, Y. H., Samoylenko, V., Tekwani, B. L., Khan, I. A., Miller, L. S., Chaurasiya, N. D., ... & Muhammad, I. | Journal of ethnopharmacology | 21 April 2010

The persistence of the subjective in neuropsychopharmacology: observations of contemporary hallucinogen research

Langlitz, N. | History of Human Sciences | February 2010

Psychedelics and the Human Receptorome

Ray, T. S. | PLoS ONE | 2 February 2010

LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor

Halberstadt, A. L, & Geyer, M. A. | Psychopharmacology | 25 November 2009

The Neurochemical Effects of Harmine in Animal Models of Depression

Fortunato, J. J. | PhD thesis | 2009

When the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor

Su, T., Hayashi, T., & Vaupel, D. B. | Science Signaling | 10 March 2009

How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale

Johansen, P. Ø., & Krebs, T. S.| Journal of Psychopharmacology | 9 March 2009

Endogenous hallucinogens as ligands of the trace amine receptors: A possible role in sensory perception

Wallach, J. V. | Medical Hypotheses | January 2009

The Pharmacology of Lysergic Acid Diethylamide: A Review

Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. | CNS Neuroscience & Therapeutics | 11 November 2008

Serotonin-Related Psychedelic Drugs

Geyer, M. A., Nichols, D. E., & Vollenweider, F. X. | Encyclopedia of Neuroscience | 5 November 2008

Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines

Winter, J. C. | Psychopharmacology | 1 November 2008

The Phenomenology and Potential Religious Import of States of Consciousness Facilitated by Psilocybin

Richards, W. A. | Archive for the Psychology of Religion | October 2008

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann U. D., & Jesse, R. | Journal of Psychopharmacology | 1 July 2008

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., & Griffiths, R. R. | Journal of Psychopharmacology | 1 July 2008

‘Hybrid’ benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines

Schultz, D. M., Prescher, J. A., Kidd, S., Marona-Lewicka, D., Nichols, D. E., & Montea, A. | Bioorganic & Medicinal Chemistry | 1 June 2008

[Hallucinogen-induced psychological disorders]

Hermle, L., Kovar, K. A., Hewer, W., & Ruchsow, M. | Fortschritte der Neurologie-Psychiatrie | 1 June 2008

Selective 5-HT2A agonist hallucinogens: A review of pharmacological interaction and corollary perceptual effects

Kent, J. | Beta Review | 23 May 2008

The correlation between ketamine and posttraumatic stress disorder in burned service members

McGhee, L. L., Maani, C. V., Garza, T. H., Gaylord, K. M., & Black, I. H. | Journal of Trauma and Acute Care Surgery | February 2008

The behavioral pharmacology of hallucinogens

Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. | Biochemical Pharmacology | 1 January 2008

Comparative potencies of MDMA analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines

Montgomery, T., Buon, C., Eibauer, S., Guiry, P. J., Keenan, A.K., & McBean, G. J. | British Journal of Pharmacology | December 2007

Chronic Phenethylamine Hallucinogen Treatment Alters Behavioral Sensitivity to a Metabotropic Glutamate 2/3 Receptor Agonist

Benneyworth, M. A., Smith, R. L., & Sanders-Bush, E. | Neuropsychopharmacology | 24 October 2007

Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans

Carter, O. L., Hasler, F., Pettigrew, J. D., Wallis, G. M., Liu, G. B., & Vollenweider, F. X. | Psychopharmacology | 14 September 2007

Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members

Santos, R. G., Landeira-Fernandez, J., Strassman, R. J., Motta, V., & Cruz, A. P. M. | Journal of Ethnopharmacology | 27 July 2007

Psilocybin-induced stimulus control in the rat

Winter, J. C., Rice, K. C., Amorosi, D. J., & Rabin, R. A. | Pharmacology Biochemistry and Behavior | 22 June 2007

Brave New World versus Island — Utopian and Dystopian Views on Psychopharmacology

Schermer, M. H. N. | Medicine, Health Care and Philosophy | 08 May 2007

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.

González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., ... & Gingrich, J. A. | Neuron | 1 February 2007

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder

Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. | Journal of Clinical Psychiatry | November 2006

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., & McCann, U. | Psychopharmacology | 7 July 2006

Mechanisms of antiaddictive actions of ibogaine

Glick, S. D., & Maisonneuve, I. S. | Annals of the New York Academy of Sciences | 7 February 2006

Screening the receptorome for plant-based psychoactive compounds

O'connor, K. A., & Roth, B. L. | Life sciences | 22 December 2005

Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors

Carter, O. L., Burr, D. C., Pettigrew, J. D., Wallis, G. M., Hasler, F., & Vollenweider, F. X. | Journal of Cognitive neuroscience | 1 October 2005

Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers

Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, & M., Kovar, K. A. | Pharmacopsychiatry | 2005

Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims

Schönenberg, M., Reichwald, U., Domes, G., Badke, A., & Hautzinger, M. | Psychopharmacology | 13 July 2005

Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man

Passie, T., Karst, M., Wiese, B., Emrich, H. M., & Schneider, U. | Neuropsychobiology | 12 May 2005

Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine

Jacob, M. S., & Presti, D. E. | Medical Hypotheses | 4 November 2004

Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography

Riba, J., Anderer, P., Jané, F., Saletu, B., & Barbanoj, M. J. | Neuropsychobiology | 1 June 2004

Hallucinogens

Nichols, D. E. | Pharmacology & therapeutics | 28 January 2004

Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebocontrolled dose-effect study

Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. | Psychopharmacology | 13 November 2003

Hallucinogens: An update

Halpern, J. H. | Current psychiatry reports | 01 Sep 2003

Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics

Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. | Journal of Pharmacology and Experimental Therapeutics | 1 July 2003

Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism

Schwarz, M. J., Houghton, P. J., Rose, S., Jenner, P., & Lees, A. D. | Pharmacology Biochemistry and Behavior | 14 June 2003

Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features.

Lerner, A. G., Gelkopf, M., Skladman, I., Rudinski, D., Nachshon, H., & Bleich, A. | International clinical psychopharmacology | 1 March 2003

Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia

Umbricht, D., Vollenweider, F. X., Schmid, L., Gruebel, C., Skrabo, A., Huber, T., & Koller, R. | Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology | 1 Februari 2003

Effects of different subanaesthetic doses of (S)-ketamine on psychopathology and binocular depth inversion in man

Passie, T., Karst, M., Borsutzky, M., Wiese, B., Emrich, H. M., & Schneider, U. | Journal of Psychopharmacology | 1 January 2003

Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up

Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. | Journal of substance abuse treatment | June 24, 2002

Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers

Riba, J., Anderer, P., Morte, A., Urbano, G., Jané, F., Saletu, B., & Barbanoj, M. J. | British journal of clinical pharmacology | 24 June 2002

The pharmacology of psilocybin

Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. | Addiction Biology | 30 May 2002

Flashback and Hallucinogen Persisting Perception Disorder: clinical aspects and pharmacological treatment approach.

Lerner, A. G., Gelkopf, M., Skladman, I., & Oyffe, I. | The Israel journal of psychiatry and related sciences | 1 January 2002

No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study

Gamma, A., Buck, A., Berthold, T., & Vollenweider, F. X. | Journal of clinical psychopharmacology | 01 February 2001

LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study.

Lerner, A. G., Gelkopf, M., Oyffe, I., Finkel, B., Katz, S., Sigal, M., & Weizman, A. | International clinical psychopharmacology | 1 January 2000

Role of Serotoninergic Neurons and 5-HT Receptors in the Action of Hallucinogens

Nichols, D. E. | Serotoninergic Neurons and 5-HT Receptors in the CNS | 1 January 2000

Pharmacokinetics of Hoasca alkaloids in healthy humans

Callaway, J. C., McKenna, D. J., Grob, C. S., Brito, G. S., Raymon, L. P., Poland, R. E., ... & Mash, D. C. | Journal of ethnopharmacology | 1 June 1999

Do entheogen-induced mystical experiences boost the immune system? Psychedelics, peak experiences, and wellness

Roberts, T. B. | Advances in Mind-Body Medicine | 1999

Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., Bäbler, A., Vogel, H., & Hell, D. | Neuroreport | 1 Dec 1998

Serotonergic Agents That Activate 5HT2A Receptors Prevent NMDA Antagonist Neurotoxicity

Farber, N. B., Hanslick, J., Kirby, C., McWilliams, L., & Olney, J. W. | Neuropsychopharmacology | 2 July 1997

Ketamine psychedelic therapy (KPT): a review of the results of ten years of research

Krupitsky, E. M., & Grinenko, A. Y. | Journal of psychoactive drugs | 1997

Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine’s putative anti-addictive activity

Sweetnam, P. M., Lancaster, J., Snowman, A., Collins, J. L., Perschke, S., Bauer, C., & Ferkany, J. | Psychopharmacology | 2 April 1995

Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens

Nichols, D. E. | Journal of psychoactive drugs | 1 January 1986

Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca

McKenna, D. J., Towers, G. N., & Abbott, F. | Journal of ethnopharmacology | 1 April 1984

LSD-assisted psychotherapy in patients with terminal cancer

Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A. | International pharmacopsychiatry | 1973

LSD-assisted psychotherapy and the human encounter with death

Richards, W., Grof, S., Goodman, L., & Kurland, A. | Journal of Transpersonal Psychology | 1972

Psychedelic Agents in Creative Problem-Solving: A Pilot Study

Harman, W. W., McKim, R. H., Mogar, R. E., Fadiman, J., & Stolaroff, M. J. | Psychological Reports | 12 April 1966

Schizophrenia: A New Approach (Continued)

Osmond, H., & Hoffer, A. | The British Journal of Psychiatry | July 1959

5‐Hydroxytryptamine. Pharmacological action and destruction in perfused lungs

Gaddum, J. H., Hebb, C. O., Silver, A., & Swan, A. A. B. | Quarterly journal of experimental physiology and cognate medical sciences | 10 Oct 1953